76.75MMarket Cap
LossP/E TTM
NeOnc Technologies Holdings Inc
Key Figures
3.450Open
3.704High
63.36KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.29%Turnover Ratio
3.490Prev. Close
3.350Low
151.38KTurnover
LossP/E Static
-4.38P/B
0.00%Div Yield TTM
-1991.59%ROA
12.99052wk High
1.70Volume Ratio
-11.90MNet Profit
21.99MShares
-3.2036EPS TTM
--Beta
--ROE
3.20052wk Low
10.14%Amplitude
100.00%Gross Margin
76.75MMarket Cap
-3.46Reward/Risk
6.34%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
NeOnc Technologies Holdings Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 149 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
NeOnc Technologies Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
NeOnc Technologies Holdings Inc Highlights
StrengthsRisks
NeOnc Technologies Holdings Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
NeOnc Technologies Holdings Inc
NTHI
3
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
NeOnc Technologies Holdings Inc Info
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
Ticker SymbolNTHI
CompanyNeOnc Technologies Holdings Inc
CEOHeshmatpour (Amir F)
Websitehttps://neonc.com/
Shareholders
FAQs
What is the current price of NeOnc Technologies Holdings Inc (NTHI)?
The current price of NeOnc Technologies Holdings Inc (NTHI) is 3.49.
What is the symbol of NeOnc Technologies Holdings Inc?
The ticker symbol of NeOnc Technologies Holdings Inc is NTHI.
What is the 52-week high of NeOnc Technologies Holdings Inc?
The 52-week high of NeOnc Technologies Holdings Inc is 12.99.
What is the 52-week low of NeOnc Technologies Holdings Inc?
The 52-week low of NeOnc Technologies Holdings Inc is 3.20.
What is the market capitalization of NeOnc Technologies Holdings Inc?
The market capitalization of NeOnc Technologies Holdings Inc is 76.75M.
Is NeOnc Technologies Holdings Inc (NTHI) currently rated as Buy, Hold, or Sell?
According to analysts, NeOnc Technologies Holdings Inc (NTHI) has an overall rating of Buy, with a price target of 16.00.
What is the Earnings Per Share (EPS TTM) of NeOnc Technologies Holdings Inc (NTHI)?
The Earnings Per Share (EPS TTM) of NeOnc Technologies Holdings Inc (NTHI) is -3.20.
